These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 36454113)

  • 1. Correlation between α-synuclein and fatty acid composition in jejunum of rotenone-treated mice is dependent on acyl chain length.
    Hajduchova D; Holic R; Gajdos P; Certik M; Halasova E; Pecova R; Pokusa M
    Gen Physiol Biophys; 2022 Nov; 41(6):523-533. PubMed ID: 36454113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroprotection of Rotenone-Induced Parkinsonism by Ursolic Acid in PD Mouse Model.
    Zahra W; Rai SN; Birla H; Singh SS; Rathore AS; Dilnashin H; Singh R; Keswani C; Singh RK; Singh SP
    CNS Neurol Disord Drug Targets; 2020; 19(7):527-540. PubMed ID: 32787765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage.
    Sherer TB; Betarbet R; Stout AK; Lund S; Baptista M; Panov AV; Cookson MR; Greenamyre JT
    J Neurosci; 2002 Aug; 22(16):7006-15. PubMed ID: 12177198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bilateral upregulation of α-synuclein expression in the mouse substantia nigra by intracranial rotenone treatment.
    Carriere CH; Kang NH; Niles LP
    Exp Toxicol Pathol; 2017 Feb; 69(2):109-114. PubMed ID: 27986376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic Systemic Exposure to Low-Dose Rotenone Induced Central and Peripheral Neuropathology and Motor Deficits in Mice: Reproducible Animal Model of Parkinson's Disease.
    Miyazaki I; Isooka N; Imafuku F; Sun J; Kikuoka R; Furukawa C; Asanuma M
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32375371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intranasal Exposure to Low-Dose Rotenone Induced Alpha-Synuclein Accumulation and Parkinson's Like Symptoms Without Loss of Dopaminergic Neurons.
    Sharma M; Kaur J; Rakshe S; Sharma N; Khunt D; Khairnar A
    Neurotox Res; 2022 Feb; 40(1):215-229. PubMed ID: 34817799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain Effects of
    Mendes D; Peixoto F; Oliveira MM; Andrade PB; Videira RA
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered fatty acid composition of dopaminergic neurons expressing alpha-synuclein and human brains with alpha-synucleinopathies.
    Sharon R; Bar-Joseph I; Mirick GE; Serhan CN; Selkoe DJ
    J Biol Chem; 2003 Dec; 278(50):49874-81. PubMed ID: 14507911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene therapy of yeast NDI1 on mitochondrial complex I dysfunction in rotenone-induced Parkinson's disease models in vitro and vivo.
    Li H; Sun B; Huang Y; Zhang J; Xu X; Shen Y; Chen Z; Yang J; Shen L; Hu Y; Gu H
    Mol Med; 2022 Mar; 28(1):29. PubMed ID: 35255803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Valproic acid is neuroprotective in the rotenone rat model of Parkinson's disease: involvement of alpha-synuclein.
    Monti B; Gatta V; Piretti F; Raffaelli SS; Virgili M; Contestabile A
    Neurotox Res; 2010 Feb; 17(2):130-41. PubMed ID: 19626387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Stearoyl-Coenzyme A Desaturase Inhibitor Prevents Multiple Parkinson Disease Phenotypes in α-Synuclein Mice.
    Nuber S; Nam AY; Rajsombath MM; Cirka H; Hronowski X; Wang J; Hodgetts K; Kalinichenko LS; Müller CP; Lambrecht V; Winkler J; Weihofen A; Imberdis T; Dettmer U; Fanning S; Selkoe DJ
    Ann Neurol; 2021 Jan; 89(1):74-90. PubMed ID: 32996158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenic Mechanisms of Cytosolic and Membrane-Enriched α-Synuclein Converge on Fatty Acid Homeostasis.
    Tripathi A; Alnakhala H; Terry-Kantor E; Newman A; Liu L; Imberdis T; Fanning S; Nuber S; Ramalingam N; Selkoe D; Dettmer U
    J Neurosci; 2022 Mar; 42(10):2116-2130. PubMed ID: 35086904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chlorogenic Acid: a Polyphenol from Coffee Rendered Neuroprotection Against Rotenone-Induced Parkinson's Disease by GLP-1 Secretion.
    Sharma N; Soni R; Sharma M; Chatterjee S; Parihar N; Mukarram M; Kale R; Sayyed AA; Behera SK; Khairnar A
    Mol Neurobiol; 2022 Nov; 59(11):6834-6856. PubMed ID: 36048341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rotenone down-regulates HSPA8/hsc70 chaperone protein in vitro: A new possible toxic mechanism contributing to Parkinson's disease.
    Sala G; Marinig D; Riva C; Arosio A; Stefanoni G; Brighina L; Formenti M; Alberghina L; Colangelo AM; Ferrarese C
    Neurotoxicology; 2016 May; 54():161-169. PubMed ID: 27133439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced firing of locus coeruleus neurons and SK channel dysfunction are conserved in distinct models of prodromal Parkinson's disease.
    Matschke LA; Komadowski MA; Stöhr A; Lee B; Henrich MT; Griesbach M; Rinné S; Geibl FF; Chiu WH; Koprich JB; Brotchie JM; Kiper AK; Dolga AM; Oertel WH; Decher N
    Sci Rep; 2022 Feb; 12(1):3180. PubMed ID: 35210472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroprotective effect of α-mangostin on mitochondrial dysfunction and α-synuclein aggregation in rotenone-induced model of Parkinson's disease in differentiated SH-SY5Y cells.
    Hao XM; Li LD; Duan CL; Li YJ
    J Asian Nat Prod Res; 2017 Aug; 19(8):833-845. PubMed ID: 28696167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The behavioural and neuropathological impact of intranigral AAV-α-synuclein is exacerbated by systemic infusion of the Parkinson's disease-associated pesticide, rotenone, in rats.
    Mulcahy P; O'Doherty A; Paucard A; O'Brien T; Kirik D; Dowd E
    Behav Brain Res; 2013 Apr; 243():6-15. PubMed ID: 23295396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction between subclinical doses of the Parkinson's disease associated gene, α-synuclein, and the pesticide, rotenone, precipitates motor dysfunction and nigrostriatal neurodegeneration in rats.
    Naughton C; O'Toole D; Kirik D; Dowd E
    Behav Brain Res; 2017 Jan; 316():160-168. PubMed ID: 27585560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. shRNA targeting α-synuclein prevents neurodegeneration in a Parkinson's disease model.
    Zharikov AD; Cannon JR; Tapias V; Bai Q; Horowitz MP; Shah V; El Ayadi A; Hastings TG; Greenamyre JT; Burton EA
    J Clin Invest; 2015 Jul; 125(7):2721-35. PubMed ID: 26075822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upregulation of Cellular Palmitoylation Mitigates α-Synuclein Accumulation and Neurotoxicity.
    Ho GPH; Ramalingam N; Imberdis T; Wilkie EC; Dettmer U; Selkoe DJ
    Mov Disord; 2021 Feb; 36(2):348-359. PubMed ID: 33103814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.